CSD500 Patents granted

Futura Medical PLC
09 May 2007


For immediate release                                        9 May 2007

                               Futura Medical Plc

                          ('Futura' or 'the Company')

                     CSD500 patents granted in 30 countries

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for consumer healthcare, announces that, in the run-up to the
commercial launch of its novel condom CSD500, patents have been granted, or are
proceeding to grant, in 30 consumer markets including the principal territories
within Europe, the US and Canada.

Futura has submitted patent applications internationally to protect its unique
intellectual property in a total of 38 countries and expects to receive patent
grants in all of these countries in due course.

CSD500, which will be marketed by SSL International plc (SSL) as a Durex(R)
branded condom, contains an erectogenic gel known as Zanifil(R) which will help
healthy men maintain a firm erection whilst wearing the condom. Futura and SSL
are currently preparing for the market launch of CSD500 which will follow the
anticipated marketing authorisation within the EU in the fourth quarter of 2007.
Futura will receive a milestone payment once marketing authorisation for CSD500
is granted within the EU, and royalty based payments from future sales of the
condom.

James Barder, Futura Medical's Chief Executive, said: 'We are delighted with the
progress we have made with our patent applications as IP protection will
underpin our revenue streams from CSD500 following the commercial launch of the
product by our marketing partner SSL.'

For further information:
Futura Medical plc
James Barder, Chief Executive                      Tel: [phone]
mail to: [e-mail]            www.futuramedical.co.uk

Canaccord Adams                                    Tel: [phone]
Mark Ashurst
Tyler Broda

Media enquiries:
Buchanan Communications
Mark Court / Rebecca Dietrich                      Tel: [phone]



Notes

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare. The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.

www.futuramedical.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange